Model parameters
| Conventional regimen* | Source | BPaL* | Source | |||||
| Treatment parameters probabilities | % | % | ||||||
| LTFU while on treatment | 18.6 | (25) | 1.4 | (11) | ||||
| Permanently discontinuing treatment due to adverse events | 14.1 | (23) | 14.1 | (23) | ||||
| Dying during treatment | 11.8 | (25) | 8.5 | (11) | ||||
| Dying after LTFU (monthly) | 2.7 | (22) | 2.7 | (22) | ||||
| Dying after permanently discontinuing treatment | 11.8 | (25) | 8.5 | (11) | ||||
| Resuming treatment after LTFU | 16.4 | (22) | 16.4 | (22) | ||||
| Hospitalisation after permanently discontinuing treatment | 10 | (24) | 10 | (24) | ||||
| Switching to conventional regimen after permanently discontinuing BPaL | NA | 50 | Assumption | |||||
| Treatment completion | 58 | Derived from model | 78 | Derived from model | ||||
| Natural cure if LTFU or permanently discontinuing treatment | 21 | Derived from model | 13 | Derived from model | ||||
| Conventional regimen | Source | BPaL | Source | |||||
| Indonesia | Kyrgyzstan | Nigeria | Indonesia | Kyrgyzstan | Nigeria | |||
| Cost parameters US$ | ||||||||
| Average monthly drug costs | 378.90 | 541.93 | 298.12 | Online supplemental table S2 | 534.50 | 186.84 | 191.39 | Online supplemental table S2 |
| Average monthly treatment management costs | 173.41 | 126.76 | 453.95 | Online supplemental table S2 | 225.32 | 188.92 | 493.38 | Online supplemental table S2 |
| Cohort parameters | ||||||||
| Annual XDR-TB patients treated with regimen—nr (%) | ||||||||
| 2020 | 58 (100) | 167 (100) | 250 (100) | Gupta et al (submitted) | 0 (0) | 0 (0) | 0 (0) | Gupta et al. (submitted) |
| 2021 | 61 (100) | 175 (100) | 275 (100) | Gupta et al (submitted) | 0 (0) | 0 (0) | 0 (0) | Gupta et al. (submitted) |
| 2022 | 32 (50) | 184 (100) | 138 (50) | Gupta et al. (submitted) | 32 (50) | 0 (0) | 138 (50) | Gupta et al. (submitted) |
| 2023 | 33 (50) | 135 (70) | 75 (25) | Gupta et al. (submitted) | 33 (50) | 58 (30) | 225 (75) | Gupta et al. (submitted) |
| 2024 | 34 (50) | 78 (38%) | 88 (25) | Gupta et al. (submitted) | 34 (50) | 125 (62) | 263 (75) | Gupta et al. (submitted) |
*Assumed similar probabilities across the three countries.
BPaL, bedaquiline, pretomanid and linezolid; LTFU, lost to follow-up; XDR-TB, extensively drug-resistant tuberculosis.